Study: Finger-Prick Blood Test Validated for Alzheimer’s Biomarkers

Does finger-prick blood testing meaningfully expand access to Alzheimer’s screening, or are key clinical and implementation questions still unresolved?

Published 1 day ago

Study: Finger-Prick Blood Test Validated for Alzheimer’s Biomarkers

story

Above: MRI scan showing early signs of Alzheimer’s disease in London, U.K., on May 30, 2025. Image credit: Peter Dazeley/Getty Images

The Spin

Techno-optimist narrative

The DROP-AD study signals a practical breakthrough in Alzheimer’s detection by validating finger-prick dried blood spot testing for key biomarkers, including p-tau217, GFAP and NfL. By enabling accurate, room-temperature samples that can be self-collected and mailed, the approach could make screening faster, cheaper and widely accessible — supporting earlier identification, earlier treatment pathways and large-scale population monitoring. The test also has potential for other neurodegenerative diseases such as Parkinson’s, ALS and MS.

NIHR Manchester Clinical Research Facility X

Techno-skeptic narrative

While the DROP-AD findings are promising, past experience with Alzheimer’s blood tests urges caution. Earlier commercial screeners have shown high false-positive rates, and major groups like the Alzheimer’s Association caution that blood biomarkers cannot yet stand alone for diagnosis. Experts note that accuracy, interpretation, disclosure and real-world implementation — especially in primary care — require further validation before widespread clinical use.

Study: Finger-Prick Blood Test Validated for Alzheimer’s Biomarkers

The Spin

Techno-optimist narrative

Techno-skeptic narrative

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters